Cargando…
Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
INTRODUCTION: Chimeric antigen receptor (CAR) T cell therapy has achieved unprecedented efficacy recently. However, the factors related to responses and durable remission are elusive. This study was to investigate the impact of pre-lymphodepletion (pre-LD) absolute lymphocyte count (ALC) on CAR T ce...
Autores principales: | Lu, Yanyan, Zhu, Hong, Liu, Yang, Wang, Ying, Sun, Yinxiang, Cheng, Hai, Yan, Zhiling, Cao, Jiang, Sang, Wei, Zhu, Feng, Li, Depeng, Sun, Haiying, Zheng, Junnian, Xu, Kailin, Li, Zhenyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185822/ https://www.ncbi.nlm.nih.gov/pubmed/37205117 http://dx.doi.org/10.3389/fimmu.2023.1155216 |
Ejemplares similares
-
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020) -
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021) -
Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
por: Xia, Jieyun, et al.
Publicado: (2023) -
An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021) -
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)